Replies to post #233940 on Biotech Values

[DewDiligence]

I agree; moreover, the typical equipose that underlies unblinding/crossover does not pertain in this trial. The placebo patients do not have any disease when they enter the trial, and they presumably wouldn’t be helped by subsequent vaccination if they develop COVID-19 during the trial.